|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Turkey Ministry of Health. Cancer
Statistics- 2015 Report. https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/istatistik/Turkiye_Kanser_Istatistikleri_2015.pdf.
Accessed February 28, 2020.
|
|
3
|
Shankar A, Dubey A, Saini D, Singh M,
Prasad CP, Roy S, Bharati SJ, Rinki M, Singh N, Seth T, et al:
Environmental and occupational determinants of lung cancer. Transl
Lung Cancer Res. 8 (Suppl 1):S31–S49. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wu S, Zhu W, Thompson P and Hannun YA:
Evaluating intrinsic and non-intrinsic cancer risk factors. Nat
Commun. 9(3490)2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Duma N, Santana-Davila R and Molina JR:
Non-small cell lung cancer: Epidemiology, screening, diagnosis, and
treatment. Mayo Clin Proc. 94:1623–1640. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Artal Cortés Á, Calera Urquizu L and
Hernando Cubero J: Adjuvant chemotherapy in non-small cell lung
cancer: State-of-the-art. Transl Lung Cancer Res. 4:191–197.
2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Benbrahim Z, Antonia T and Mellas N: EGFR
mutation frequency in Middle East and African non-small cell lung
cancer patients: A systematic review and meta-analysis. BMC Cancer.
18(891)2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Dearden S, Stevens J, Wu YL and Blowers D:
Mutation incidence and coincidence in non small-cell lung cancer:
Meta-analyses by ethnicity and histology (mutMap). Ann Oncol.
24:2371–2376. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Thomas R and Weihua Z: Rethink of EGFR in
cancer with its kinase independent function on board. Front Oncol.
9(800)2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kujtan L and Subramanian J: Epidermal
growth factor receptor tyrosine kinase inhibitors for the treatment
of non-small cell lung cancer. Expert Rev Anticancer Ther.
19:547–559. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Leal LF, de Paula FE, De Marchi P, de
Souza Viana L, Pinto GDJ, Carlos CD, Berardinelli GN, Miziara JE,
da Silva CM, Silva ECA, et al: Mutational profile of Brazilian lung
adenocarcinoma unveils association of EGFR mutations with high
Asian ancestry and independent prognostic role of KRAS mutations.
Sci Rep. 9(3209)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Midha A, Dearden S and McCormack R: EGFR
mutation incidence in non-small-cell lung cancer of adenocarcinoma
histology: A systematic review and global map by ethnicity
(mutMapII). Am J Cancer Res. 5:2892–2911. 2015.PubMed/NCBI
|
|
13
|
World Medical Association. World medical
association declaration of Helsinki: Ethical principles for medical
research involving human subjects. JAMA. 310:2191–2194.
2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Calibasi G, Baskin Y, Alyuruk H, Cavas L,
Oztop I, Sagol O, Atila K, Ellidokuz H and Yilmaz U: Molecular
analysis of the KIT gene in gastrointestinal stromal tumors with
novel mutations. Appl Immunohistochem Mol Morphol. 22:37–45.
2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Weyant GW, Wisotzkey JD, Benko FA and
Donaldson KJ: BRAF mutation testing in solid tumors: A
methodological comparison. J Mol Diagn. 16:481–485. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bihl MP, Hoeller S, Andreozzi MC, Foerster
A, Rufle A, Tornillo L and Terracciano L: KRAS mutation testing in
colorectal cancer: Comparison of the results obtained using 3
different methods for the analysis of codons G12 and G13. Diagn Mol
Pathol. 21:14–23. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Dean AG, Sullivan KM and Soe MM: OpenEpi:
Open source epidemiologic statistics for public health http://www.openepi.comsimplewww.openepi.com,
Accessed February 28, 2020.
|
|
18
|
R Core Team: R: A language and environment
for statistical computing. R Foundation for Statistical Computing,
Vienna, Austria, 2012. ISBN 3-900051-07-0, URL http://www.R-project.org/.
|
|
19
|
Hammoudeh ZA, Antonova O, Staneva R,
Nikolova D, Kyuchukov Y, Penev A, Mintchev T, Koleva V, Hadjidekova
S and Toncheva D: Detecting EGFR mutations in patients with
non-small cell lung cancer. Balkan J Med Genet. 21:13–17.
2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Liam CK, Wahid MI, Rajadurai P, Cheah YK
and Ng TS: Epidermal growth factor receptor mutations in lung
adenocarcinoma in Malaysian patients. J Thorac Oncol. 8:766–772.
2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Errihani H, Inrhaoun H, Boukir A, Kettani
F, Gamra L, Mestari A, Jabri L, Bensouda Y, Mrabti H and
Elghissassi I: Frequency and type of epidermal growth factor
receptor mutations in moroccan patients with lung adenocarcinoma. J
Thorac Oncol. 8:1212–1214. 2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Papadopoulou E, Tsoulos N, Tsirigoti A,
Apessos A, Agiannitopoulos K, Metaxa-Mariatou V, Zarogoulidis K,
Zarogoulidis P, Kasarakis D, Kakolyris S, et al: Determination of
EGFR and KRAS mutational status in Greek non-small cell lung cancer
patients. Oncol Lett. 10:2176–2184. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Syrigos KN, Georgoulias V, Zarogoulidis K,
Makrantonakis P, Charpidou A and Christodoulou C: Epidemiological
characteristics, EGFR status and management patterns of advanced
non-small cell lung cancer patients: The Greek REASON Observational
Registry Study. Anticancer Res. 38:3735–3744. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Vázquez S, Casal J, Afonso Afonso FJ,
Fírvida JL, Santomé L, Barón F, Lázaro M, Pena C, Amenedo M,
Abdulkader I, et al: VEGFR testing and clinical management of
advanced NSCLC: A Galician Lung Cancer Group study (GGCP 048-10).
Cancer Manag Res. 8:11–20. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Szumera-Ciećkiewicz A, Olszewski WT,
Tysarowski A, Kowalski DM, Głogowski M, Krzakowski M, Siedlecki JA,
Wągrodzki M and Prochorec-Sobieszek M: EGFR mutation testing on
cytological and histological samples in non-small cell lung cancer:
A Polish, single institution study and systematic review of
European incidence. Int J Clin Exp Pathol. 6:2800–2812.
2013.PubMed/NCBI
|
|
26
|
Fakhruddin N, Mahfouz R, Farhat F, Tfayli
A, Abdelkhalik R, Jabbour M, Yehia L, Mahfoud Z and Zaatari G:
Epidermal growth factor receptor and KRAS mutations in lung
adenocarcinoma: A retrospective study of the Lebanese population.
Oncol Rep. 32:2223–2229. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Haghgoo SM, Khosravi A, Mortaz E,
Pourabdollah-Toutkaboni M, Seifi S, Sabour S and Allameh A:
Prognostic value of rare and complex mutations in EGFR and serum
levels of soluble EGFR and its ligands in non-small cell lung
carcinoma patients. Clin Biochem. 6:293–300. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Jazieh AR, Jaafar H, Jaloudi M, Mustafa
RS, Rasul K, Zekri J and Gasmelseed A: Patterns of epidermal growth
factor receptor mutation in non-small-cell lung cancers in the Gulf
region. Mol Clin Oncol. 3:1371–1374. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Bircan S, Baloglu H, Kucukodaci Z and
Bircan A: EGFR and KRAS mutations in Turkish non-small cell lung
cancer patients: A pilot study. Med Oncol. 31(87)2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Unal OU, Oztop I, Calibasi G, Baskin Y,
Koca D, Demir N, Akman T, Ellidokuz H and Yilmaz AU: Relationship
between epidermal growth factor receptor gene mutations and
clinicopathological features in patients with non-small cell lung
cancer in western Turkey. Asian Pac J Cancer Prev. 14:3705–3709.
2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR,
Threapleton D, Yang ZY, Mao C and Tang JL: The prevalence of EGFR
mutation in patients with non-small cell lung cancer: A systematic
review and meta-analysis. Oncotarget. 7:78985–78993.
2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tu HY, Ke EE, Yang JJ, Sun YL, Yan HH,
Zheng MY, Bai XY, Wang Z, Su J, Chen ZH, et al: A comprehensive
review of uncommon EGFR mutations in patients with non-small cell
lung cancer. Lung Cancer. 114:96–102. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Lund-Iversen M, Kleinberg L,
Fjellbirkeland L, Helland Å and Brustugun OT: Clinicopathological
characteristics of 11 NSCLC patients with EGFR-exon 20 mutations. J
Thorac Oncol. 7:1471–1473. 2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Yatabe Y, Kerr KM, Utomo A, Rajadurai P,
Tran VK, Du X, Chou TY, Enriquez ML, Lee GK, Iqbal J, et al: EGFR
mutation testing practices within the Asia Pacific region: Results
of a multicenter diagnostic survey. J Thorac Oncol. 10:438–445.
2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Pirker R, Herth FJ, Kerr KM, Filipits M,
Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, et
al: Consensus for EGFR mutation testing in non-small cell lung
cancer: Results from a European workshop. J Thorac Oncol.
5:1706–1713. 2010.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Massarelli E, Johnson FM, Erickson HS,
Wistuba II and Papadimitrakopoulou V: Uncommon epidermal growth
factor receptor mutations in non-small cell lung cancer and their
mechanisms of EGFR tyrosine kinase inhibitors sensitivity and
resistance. Lung Cancer. 80:235–241. 2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lee B, Lee T, Lee SH, Choi YL and Han J:
Clinicopathologic characteristics of EGFR, KRAS, and ALK
alterations in 6,595 lung cancers. Oncotarget. 7:23874–23884.
2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Tomizawa Y, Iijima H, Sunaga N, Sato K,
Takise A, Otani Y, Tanaka S, Suga T, Saito R, Ishizuka T, et al:
Clinicopathologic significance of the mutations of the epidermal
growth factor receptor gene in patients with non-small cell lung
cancer. Clin Cancer Res. 11:6816–6822. 2005.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Suda K, Onozato R, Yatabe Y and Mitsudomi
T: EGFR T790M mutation: A double role in lung cancer cell survival?
J Thorac Oncol. 4:1–4. 2009.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Siegelin MD and Borczuk AC: Epidermal
growth factor receptor mutations in lung adenocarcinoma. Lab
Invest. 94:129–137. 2014.PubMed/NCBI View Article : Google Scholar
|
